Clinical trials: Arterial Obstructive Diseases
Coronary Artery Disease, Atrial Fibrillation
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
The study aims to evaluate the safety and effectiveness comparisons between warfarin, dabigatran, and rivaroxaban in routine clinical practice among Japanese non-valvular atrial fibrillation (NVAF) patients with concomitant…
- Trial name
- NCT05051904
- Where
- Germany
- Volunteers
- 39,357 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Aspirin Resistance in Coronary Artery Disease
The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease.
- Trial name
- NCT00753935
- Testing
- enteric-coated aspirin, Chewable aspirin
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Vanderbilt University
Coronary Artery Disease
A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias
The purpose of this investigation is to determine the prevalence of device-recorded ST segment changes occurring before appropriate Implantable Cardiac Defibrillator (ICD) therapies (ATP or Shock) and to define their temporal…
- Trial name
- inSighT (NCT01685047)
- Where
- Germany
- Volunteers
- 481 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.
- Trial name
- SIGNIFY (NCT02446990)
- Testing
- Ivabradine
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 19,102 people
- Sponsor
- Institut de Recherches Internationales Servier
Coronary Artery Disease, Acute Coronary Syndrome
Tailored Antiplatelet Therapy Following PCI
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation.
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
- Trial name
- TAILOR-PCI (NCT01742117)
- Testing
- Clopidogrel, Ticagrelor
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 5,276 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
- Trial name
- GENERATIONS (NCT01107912)
- Testing
- prasugrel, clopidogrel
- Where
- 7 sites in United States, Ireland and 2 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Coronary Disease, Coronary Artery Disease
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT00531011)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System, TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Metabolic Syndrome X, Overweight
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455403)
- Testing
- Chloroquine
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Bypass, Myocardial Ischemia
Glutamate for Metabolic Intervention in Coronary Surgery
The main purpose of this study is to determine whether intravenous glutamate infusion given in association with surgery for unstable coronary artery disease can protect the heart from myocardial injury, postoperative heart…
- Conditions
- Coronary Artery Bypass, Myocardial Ischemia, Myocardial Infarction, Coronary Artery Disease
- Trial name
- GLUTAMICS (NCT00489827)
- Testing
- Intravenous infusion of saline, Intravenous glutamate infusion
- Where
- 3 sites in Sweden
- Volunteers
- 865 people
- Sponsor
- University Hospital, Linkoeping
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
Coronary Artery Disease, Myocardial Ischemia
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
Not infrequently, a physician is faced with uncertainty regarding the ability of a patient to perform adequate exercise in the noninvasive evaluation of known or suspected coronary artery disease (CAD) by the use of radionuclide…
- Trial name
- NCT01021618
- Testing
- Regadenoson, Symptom-limited exercise
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Hartford Hospital
Arterial Occlusion, Cardiovascular Diseases
Comparing TR Band to Statseal in Conjunction With TR Band II
The purpose of this clinical study is to compare how well two different devices for achieving hemostasis perform in patients undergoing transradial procedures.
- Conditions
- Arterial Occlusion, Cardiovascular Diseases, Atherosclerosis, Hematoma
- Trial name
- Statseal II (NCT04046952)
- Testing
- Statseal with TR Band, TR band only
- Where
- United States
- Volunteers
- 443 people
- Sponsor
- VA Long Beach Healthcare System
Critical Limb Ischemia
PROMISE International
The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
- Trial name
- NCT03321552
- Testing
- Percutaneous deep vein arterialization, LimFlow System
- Where
- 12 sites in Austria, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- LimFlow SA
Metabolic Syndrome X, Overweight
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455325)
- Testing
- Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Disease
TAXUS PERSEUS Workhorse
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo…
- Trial name
- PERSEUS WH (NCT00484315)
- Testing
- Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
- Where
- 90 sites in United States, Australia and 2 more
- Volunteers
- 1,264 people
- Sponsor
- Boston Scientific Corporation
Peripheral Arterial Disease (PAD)
Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease
The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug…
- Trial name
- INPACT SFA I (NCT01175850)
- Testing
- Drug-Coated Balloon (DCB), PTA Balloon: Balloon Angioplasty
- Where
- Germany
- Volunteers
- 331 people
- Sponsor
- Medtronic Endovascular
Coronary Artery Disease (CAD)
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or…
- Trial name
- NCT01334918
- Testing
- regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast
- Where
- 11 sites in United States
- Volunteers
- 124 people
- Sponsor
- Astellas Pharma Inc
Peripheral Arterial Disease
Clinical Evaluation of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease
This is a BlueDop Vascular Expert System (BVE) Post-Market Clinical Follow-Up (PMCF) study. The primary objective of the study is to assess the clinical applicability and diagnostic accuracy of the BVE device in subjects who…
- Trial name
- NCT05073510
- Testing
- BVE
- Where
- 4 sites in Spain
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- BlueDop Medical LTD
Cognitive Manifestations
Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates
Carotid artery plaques are known to cause stroke. Cognitive impairment is an insidious but poorly understood problem in patients with carotid plaques.
- Trial name
- ACCOF (NCT01353196)
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- VA Office of Research and Development
Cardiac Disease, Coronary Artery Disease
Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)
The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery access site in patients on anticoagulation who…
- Trial name
- NCT01600482
- Testing
- CELT ACD
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 241 people
- Sponsor
- Vasorum Ltd